These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3459351)

  • 1. A comparison of different formulations and dosage administrations of gemfibrozil.
    Kovanen PT; Koskinen P; Manninen V
    Am J Cardiol; 1986 May; 57(14):31G-34G. PubMed ID: 3459351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil also corrects dyslipidemia in postmenopausal women and smokers.
    Koskinen P; Kovanen PT; Tuomilehto J; Manninen V
    Arch Intern Med; 1992 Jan; 152(1):90-6. PubMed ID: 1728934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
    Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type III hyperlipoproteinemia with four different treatment regimens.
    Hoogwerf BJ; Bantle JP; Kuba K; Frantz ID; Hunninghake DB
    Atherosclerosis; 1984; 51(2-3):251-9. PubMed ID: 6588975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term use of gemfibrozil (Lopid) in the treatment of dyslipidemia.
    Lewis JE
    Angiology; 1982 Sep; 33(9):603-12. PubMed ID: 6957156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemfibrozil therapy in primary type II hyperlipoproteinemia: effects on lipids, lipoproteins and apolipoproteins.
    Lupien PJ; Brun D; Gagné C; Moorjani S; Bielman P; Julien P
    Can J Cardiol; 1991; 7(1):27-33. PubMed ID: 2025787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of gemfibrozil on lipoprotein metabolism.
    Saku K; Gartside PS; Hynd BA; Kashyap ML
    J Clin Invest; 1985 May; 75(5):1702-12. PubMed ID: 3923042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects.
    Jones PH; Pownall HJ; Patsch W; Herd JA; Farmer JA; Payton-Ross C; Kimball KT; Gotto AM; Morrisett JD
    J Lipid Res; 1996 Jun; 37(6):1298-308. PubMed ID: 8808764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein changes associated with the plasma lipid-regulating activity of gemfibrozil in cholesterol-fed rats.
    Krause BR; Newton RS
    J Lipid Res; 1985 Aug; 26(8):940-9. PubMed ID: 3862732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of gemfibrozil on high-density lipoproteins.
    Glueck C
    Am J Cardiol; 1983 Aug; 52(4):31B-34B. PubMed ID: 6577782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil on serum lipids in man.
    Fenderson RW; Deutsch S; Menachemi E; Chin B; Samuel P
    Angiology; 1982 Sep; 33(9):581-93. PubMed ID: 6751166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Helsinki Heart Study: basic design and randomization procedure.
    Mänttäri M; Elo O; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    Eur Heart J; 1987 Oct; 8 Suppl I():1-29. PubMed ID: 3322826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma prekallikrein, kallikrein inhibitors, kininogen and lipids during gemfibrozil treatment in type II dyslipidaemia.
    Torstila I; Kaukola S; Manninen V; Virtamo J; Mälkönen M
    Acta Med Scand Suppl; 1982; 668():123-9. PubMed ID: 6188330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemfibrozil in the treatment of resistant familial hypercholesterolaemia and type III hyperlipoproteinaemia.
    Houlston R; Quiney J; Watts GF; Lewis B
    J R Soc Med; 1988 May; 81(5):274-6. PubMed ID: 3164409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia.
    Civeira F; Cenarro A; Ferrando J; Puzo J; Garcia-Otín AL; Mozas P; Pocoví M
    Am Heart J; 1999 Jul; 138(1 Pt 1):156-62. PubMed ID: 10385780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
    Stange EF; Osenbrügge M; Rustan M; Reimann F; Schneider A; Ditschuneit HH; Ditschuneit H
    Atherosclerosis; 1991 Dec; 91(3):257-65. PubMed ID: 1789808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.